About: Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis
Creator	Zhang, Chi Zhang, Zhen Zhang, Shuyang Ge, Wei-Hong Gu, Zhi-Chun Kong, Ling-Cong Königsbrügge, Oliver Le, Ke-Jia Lin, Hou-Wen Pan, Mang-Mang Shen, Long Xu, Hang
source	Medline; PMC
abstract	Background: Emerging evidence shows that coronavirus disease 2019 (COVID-19) is commonly complicated by coagulopathy, and venous thromboembolism (VTE) is considered to be a potential cause of unexplained death. Information on the incidence of VTE in COVID-19 patients, however, remains unclear. Method: English-language databases (PubMed, Embase, Cochrane), Chinese-language databases (CNKI, VIP, WANFANG), and preprint platforms were searched to identify studies with data of VTE occurrence in hospitalized COVID-19 patients. Pooled incidence and relative risks (RRs) of VTE were estimated by a random-effects model. Variations were examined based on clinical manifestations of VTE (pulmonary embolism-PE and deep vein thrombosis-DVT), disease severity (severe patients and non-severe patients), and rate of pharmacologic thromboprophylaxis (≥60 and <60%). Sensitivity analyses were conducted to strengthen the robustness of results. Meta-regression was performed to explore the risk factors associated with VTE in COVID-19 patients. Results: A total of 17 studies involving 1,913 hospitalized COVID-19 patients were included. The pooled incidence of VTE was 25% (95% CI, 19–31%; I(2), 95.7%), with a significant difference between the incidence of PE (19%; 95% CI, 13–25%; I(2), 93.2%) and DVT (7%; 95% CI, 4–10%; I(2), 88.3%; P(interaction) < 0.001). Higher incidence was observed in severe COVID-19 patients (35%; 95 CI%, 25–44%; I(2), 92.4%) than that in non-severe patients (6%; 95 CI%, 3–10%; I(2), 62.2%; P(interaction) < 0.001). The high rate of pharmacologic thromboprophylaxis in COVID-19 patients (≥60%) was associated with a lower incidence of VTE compared with the low pharmacologic thromboprophylaxis rate (<60%) (19 vs. 40%; P(interaction) = 0.052). Severe patients had a 3.76-fold increased risk of VTE compared with non-severe patients (RR, 4.76; 95% CI, 2.66–8.50; I(2), 47.0%). Sensitivity analyses confirmed the robustness of the primacy results. Conclusions: This meta-analysis revealed that the estimated VTE incidence was 25% in hospitalized COVID-19 patients. Higher incidence of VTE was observed in COVID-19 patients with a severe condition or with a low rate of pharmacologic thromboprophylaxis. Assessment of VTE risk is strongly recommended in COVID-19 patients, and effective measures of thromboprophylaxis should be taken in a timely manner for patients with high risk of VTE.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.3389/fcvm.2020.00151
bibo:pmid	32850990
has license	cc-by
sha1sum (hex)	65c706586e229ece80e7bde969eb95a8fa852754
schema:url	https://doi.org/10.3389/fcvm.2020.00151
resource representing a document's title	Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis
has PubMed Central identifier	PMC7423832
has PubMed identifier	32850990
schema:publication	Front Cardiovasc Med
resource representing a document's body	covid:65c706586e229ece80e7bde969eb95a8fa852754#body_text
is schema:about of	named entity 'Thromboembolism' named entity 'patients' named entity 'VTE' named entity 'incidence' named entity 'incidence' named entity 'timely' named entity 'VTE' named entity 'VTE' named entity 'VTE' named entity 'COVID-19' named entity 'thromboprophylaxis' named entity 'meta-analysis' named entity 'Coronavirus Disease 2019' named entity 'VTE' named entity 'meta-analysis' named entity 'VTE' named entity 'VTE' named entity 'thromboprophylaxis' named entity 'COVID-19' named entity 'VTE' named entity 'VTE' named entity 'P-values' named entity 'UFH' named entity 'Coronavirus disease 2019' named entity 'VTE' named entity 'COVID-19' named entity 'Subgroup analysis' named entity 'VTE' named entity 'sample size' named entity 'DVT' named entity 'septic shock' named entity 'sensitivity analysis' named entity 'pharmacologic' named entity 'COVID-19' named entity 'anticoagulation' named entity 'thrombotic complications' named entity 'critically ill patients' named entity 'risk ratio' named entity 'COVID-19 disease' named entity 'quality control' named entity 'thromboprophylaxis' named entity 'prophylactic' named entity 'VTE' named entity 'VTE' named entity 'cytokine storm syndrome' named entity 'LMWH' named entity 'thromboprophylaxis' named entity 'International Society on Thrombosis and Haemostasis' named entity 'CTPA' named entity 'thromboprophylaxis' named entity 'pharmacologic' named entity 'ICU' named entity 'VTE' named entity 'VTE' named entity 'VTE' named entity 'COVID-19' named entity 'pharmacologic' named entity 'metaanalysis' named entity 'ultrasonography' named entity 'thrombotic complications' named entity 'Intensive Care Unit' named entity 'COVID-19' named entity 'VTE' named entity 'DVT' named entity 'risk factors' named entity 'viral infection' named entity 'VTE' named entity 'COVID-19' named entity 'VTE' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software